Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q4 2017 · 10-K
Revenue$10.79M$10.79M+728.4% vs Q4 2016 Net Income-$17.40M-$17.40MN/M vs Q4 2016 EPS Diluted-$0.54-$0.54N/M vs Q4 2016 Operating Income-$17,583,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$13,468,000N/M Margins · derivedOperating margin-162.9%+1953.7 pt vs Q4 2016
Net margin-161.2%+1953.8 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 7, 2018 · 66 d after period end